PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis

الملخص EN

Mitotic kinases are the key components of the cell cycle machinery and play vital roles in cell cycle progression.

PLK-1 (Polo-like kinase-1) is a crucial mitotic protein kinase that plays an essential role in both the onset of G2/M transition and cytokinesis.

The overexpression of PLK-1 is strongly correlated with a wide spectrum of human cancers and poor prognosis.

The (si)RNA-mediated depletion of PLK-1 arrests tumor growth and triggers apoptosis in cancer cells without affecting normal cells.

Therefore, PLK-1 has been selected as an attractive anticancer therapeutic drug target.

Some small molecules have been discovered to target the catalytic and noncatalytic domains of PLK-1.

These domains regulate the catalytic activation and subcellular localization of PLK-1.

However, while PLK-1 inhibitors block tumor growth, they have been shown to cause severe adverse complications, such as toxicity, neutropenia, and bone marrow suppression during clinical trials, due to a lack of selectivity and specificity within the human kinome.

To minimize these toxicities, inhibitors should be tested against all protein kinases in vivo and in vitro to enhance selectivity and specificity against targets.

Here, we discuss the potency and selectivity of PLK-1-targeted inhibitors and their molecular interactions with PLK-1 domains.